Pfizer Announces Top-Line Data For Full Season Two Efficacy Of ABRYSVO For RSV In Older Adults
Portfolio Pulse from Benzinga Newsdesk
Pfizer announced that its bivalent vaccine ABRYSVO showed a 77.8% efficacy against RSV lower respiratory tract disease in adults 60 years or older through two full seasons after a single dose. This data highlights ABRYSVO's consistent high protective efficacy for both RSV A and RSV B.
February 29, 2024 | 1:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer's ABRYSVO vaccine demonstrates a 77.8% efficacy against RSV in adults 60+ over two seasons, indicating strong performance and potential market impact.
The announcement of ABRYSVO's efficacy is significant as it demonstrates the vaccine's strong performance and potential for market success. Given the high efficacy rate and the target demographic's vulnerability to RSV, this could lead to increased demand and positive market reception, potentially boosting Pfizer's stock in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100